ENTPD1 and neoplasm: Preclinical studies revealed that blocking mouse CD39 by an anti-CD39 mAb (clone B66) in a MC38 tumor mouse model drives extracellular ATP- and inflammasome-driven anti-tumor immunity with the potential to overcome anti-PD1 resistance (36).